Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01508130 · ClinicalTrials.gov registry record
An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1
A clinical trial, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 672
- Enrollment target
NCT01508130 is a clinical trial that has completed, run by Hoffmann-La Roche. The registered enrollment target is 672 participants.
The verdict
NCT01508130 has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 672 participants
- Enrollment target
Study Summary
This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1. Patients receiving pegylated interferon (e.g. Pegasys) and ribavirin plus either telaprevir or boceprivir in accordance with local standard of care and US labeling will be followed for the duration of their treatment and for up to 24 weeks post-treatment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 672 participants |
| Start Date | 2012-01-31 |
| Est. Completion | 2014-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01508130
The ClinicalTrials.gov registry entry for NCT01508130 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 672 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01508130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01508130 about?
NCT01508130 is a clinical study titled "An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1". This prospective observational study will evaluate the efficacy and safety of two approved pegylated interferon-based direct acting antiviral triple therapies in patients with chronic hepatitis C genotype 1. Patients receiving pegylated interferon (e.g. Pegasys) and ribavirin plus either telaprevir ...
What is the current status of trial NCT01508130?
This trial is currently completed. The enrollment target is 672 participants. The study started on 2012-01-31. Estimated completion is 2014-03-31.
Who is sponsoring clinical trial NCT01508130?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.